目的 探讨美托洛尔和卡维地洛对非ST段抬高型心肌梗死（NSTEMI）患者结局及γ-谷氨酰转移酶（GGT）、尿酸的影响。方法 前瞻性纳入120例NSTEMI患者，按用药不同将患者分为美托洛尔组（n=60）和卡维地洛组（n=60），分别给予琥珀酸美托洛尔缓释片47.5 mg，每日1次；卡维地洛片25 mg，每次12.5 mg，每日2次。两组均治疗3个月。此后，所有患者均接受冠状动脉造影，并进行为期12个月的随访。于入院后、造影后第1个月和第3个月抽血并检测GGT和尿酸。结果 两组患者住院时GGT和UA水平比较均无统计学差异；冠脉造影1、3月后复查，两组患者GGT和UA水平均显著低于入院时（P<0.05），但两组间比较仍均无统计学差异。此外，卡维地洛组患者主要终点总不良事件发生率显著低于美托洛尔组，差异有统计学意义（P<0.05）。结论 美托洛尔和卡维地洛没有降低NSTEMI患者GGT和尿酸水平；给予NSTEMI患者卡维地洛者短期结局优于美托洛尔。

Objective To investigate the effects of metoprolol and carvedilol on outcome and γ-glutamyltransferase (GGT) and uric acid in patients with non-ST-elevation myocardial infarction (NSTEMI). Methods Patients were enrolled in 120 patients with NSTEMI who were divided into metoprolol (n=60) and carvedilol (n=60) according to prospective randomized controlled trial. All patients were given coronary artery angiography, and for a period of 12 months follow-up. After admission, blood was collected from the first and third months after angiography and GGT and uric acid were measured. Results There was no significant difference in GGT and uric acid levels between the first and third months after admission. There was no significant difference between the patients in the carvedilol group and the carvedilol group The incidence of adverse events was significantly lower than in the metoprolol group in the primary end point (P < 0.05). Conclusion Metoprolol and carvedilol did not reduce GGT and uric acid levels in NSTEMI patients; the short-term outcome of carvedilol given to patients with NSTEMI was superior to metoprolol.